摘要
研究证实三氧化二砷（As2 O3）单药治疗肝细胞癌（HCC）的效果有限，多数学者认为主要与 HCC 的化疗耐药有关。HCC 对 As2 O3的耐药机制目前仍很不明确，研究显示与 As2 O3的代谢特点、肝癌组织学和分子生物学的特征等密切相关。
Many studies have proven that arsenic trioxide （As2 O3 ）as a single agent is not effective against hepatocellular carcinoma （HCC）.Many scholars believe that chemotherapy drug resistance of HCC to As2 O3 is the most important reason.The underlying drug resistance mechanism of HCC cells to As2 O3 remains unclear.Studies show that potential mechanism may be tightly associated with As2 O3 pharmacokinetics and properties of HCC tissues and complex molecular biology.
作者
陈耀庭
胡晓俊
李丹
单鸿
Chen Yao-ting Hu Xiaojun Li Dan Shan Hong(Center for Interventional Medicine, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China Department of Interventional Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China)
出处
《国际肿瘤学杂志》
CAS
2016年第11期861-864,共4页
Journal of International Oncology
基金
国家自然科学基金（81430041）
关键词
肝肿瘤
砷剂
抗药性
肿瘤
分子靶向治疗
Liver neoplasms
Arsenicals
Drug resistance,neoplasm
Molecular targeted therapy
